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Abstract
Percutaneous coronary intervention (PCI) of vein graft lesions is associated with a high risk of peri-procedural myocar-
dial infarction and greater mortality than routine native coronary intervention. Embolic protection devices have been 
advocated to reduce the risk of distal embolisation during vein graft PCI.
Here, we report the case of a 72 year-old diabetic male smoker who had coronary artery bypass surgery three years 
previously who presented with acute coronary syndrome. Repeat coronary angiography revealed patent grafts except for 
a discrete eccentric critical lesion in ostium of saphenous vein graft to obtuse marginal. The lesion was crossed using 
a 0.014” runthrough wire (Terumo, Japan). Intragraft diltiazem (5 mg) was administered through the guiding catheter 
each time before predilatation and stenting (total dose = 30 mg). It was finally stented by deploying a 3.5 × 23 mm 
Xience Prime everolimus-eluting stent (Abbott, USA) at 13 atm pressure achieving TIMI III flow. He was discharged the 
next day with acetylsalicylic acid — 75 mg/day, ticagrelor — 90 mg twice daily, atorvastatin — 40 mg/day, metoprolol — 
100 mg/day, and ramipril — 5 mg/day. The patient has been doing extremely well since then, with regular follow-ups 
at our institute.
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Introduction
The saphenous vein is commonly used as a graft (SVGs) 
along with the left internal mammary artery during coro-
nary artery bypass graft surgery (CABG). However, they 
have poor long-term patency compared to arterial grafts 
because they suffer both from degeneration and a failure 
rate of as high as 25% in the first 12 months [1]. Percuta-
neous coronary intervention (PCI) of vein graft lesions is 
associated with a high risk of peri-procedural myocardial 
infarction (MI) and greater mortality than routine native 
coronary PCI as a result of distal embolisation manifesting 
as the slow flow and no-reflow phenomenon (SFNR) which 
is encountered in 10–15% of cases [1]. Furthermore, de-
teriorating SVG lesions also possess thinner, more friable 
fibrous caps compared to native lesions, which further ag-
gravates the incidence of plaque embolisation and platelet 
aggregation [2]. Although what causes no-reflow remains 
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dominant circulation. Right coronary artery showed mid 
tubular 90% lesion.
CABG was done using a left internal mammary artery 
(LIMA) graft as conduit to LAD, and SVG was anastomosed 
to obtuse marginal (OM), and posterior descending arte-
ry (PDA). Repeat coronary angiography revealed patent 
LIMA and SVG to PDA while there was a discrete eccentric 
critical lesion in ostium of SVG to OM with 99% stenosis 
(Figure 1). Intervention of critical SVG was planned after 
proper consent. SVG was cannulated using a 6 F Judkins 
right (JR) guiding catheter after failing to cannulate 
with a multipurpose catheter (Figure 2). The lesion was 
crossed and parked distally using a 0.014” runthrough 
wire (Terumo, Japan). Intragraft diltiazem (5 mg) was 
administered through the guiding catheter. The lesion 
was sequentially and gradually predilated using a 2 × 
10 mm and a 2.4 × 10 mm Traveller semicompliant bal-
loon (Abbott, USA). Diltiazem (5 mg) was injected each 
time before upsizing the balloon. As the lesion was not 
properly opening up because of its fibrotic nature, it 
was further dilated using a 3 × 10 mm cutting balloon 
(Flextome, Boston Scientific, USA) at 16 atm pressure by 
further administering 5 mg diltiazem (Figure 3). It was 
finally stented by deploying a 3.5 × 23 mm Xience Prime 
everolimus-eluting stent (Abbott, USA) at 13 atm pressure 
achieving TIMI III flow (Figures 4, 5). He was discharged 
the next day with ASA — 75 mg/day, ticagrelor — 90 mg 
twice daily, atorvastatin — 40 mg/day, metoprolol — 
100 mg/day, and ramipril — 5 mg/day. The patient has 
unclear, endothelial swelling, neutrophil infiltration, and 
platelet aggregation inducing microvasculature spasm 
and obstruction are a few of the plausible mechanisms. 
Combined together, these are associated with a higher rate 
of in-stent restenosis and target vessel revascularisation 
(TVR). The severity of these potential consequences makes 
finding the optimal technique essential during invasive SVG 
revascularisation.
Case report
A 72 year-old diabetic male smoker presented with 
sudden onset chest pain radiating to the right arm of 10 
minutes’ duration with diaphoresis. Past medical history 
included CABG three years earlier in lieu of triple vessel 
disease involving distal left main bifurcation. He was 
receiving acetylsalicylic acid (ASA) — 75 mg, metoprolol 
— 100 mg, atorvastatin — 20 mg, and ramipril — 5 mg, 
and gilbenclaimide daily. His vitals, physical examination, 
and biochemistry were all unremarkable. Electrocardio-
gram revealed mild ST-T changes in precordial leads. 
Echocardiography revealed mild concentric hypertrophy 
of left ventricle, and grade-II diastolic dysfunction with 
normal ejection fraction (EF = 55%). His troponin T level 
was raised (0.4 ng/L) when measured six hours after 
presentation. His coronary angiography three years be-
fore had revealed a left main bifurcation lesion (medina 
class: 1, 1, 1) involving the left anterior descending 
artery (LAD) and the left circumflex artery (LCx) with left 
A B
Figure 1A, B. Aorto-ostial lesion of saphenous vein graft to obtuse marginal showing discrete eccentric critical lesion (A — antero-posterior 
view; B — straight lateral view)
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been doing excellently since then with regular follow-ups 
at our institute.
Discussion
Embolic protection devices (EPD) have been advocated in 
the American Heart Association/American College of Car-
diology/Society For Cardiac Angiography And Interventions 
(AHA/ACC/SCAI) percutaneous coronary intervention (PCI) 
guidelines, when technically feasible, to reduce the risk of 
distal embolisation during SVG PCI. These guidelines were 
influenced by the SAFER (Saphenous vein graft Angioplasty 
Free of Emboli Randomized) study, a single randomised 
controlled trial which showed a significant reduction in ma-
jor adverse cardiac events (MACE) with the use of a distal 
balloon occlusion device [3, 4].
There are several different types of commercially ava-
ilable embolic protection device with well-established effi-
cacy, including the Filter wire/Spider/TRAP distal embolic 
filter, the Guardwire distal occlusion/aspiration device, and 
the Proxis proximal occlusion/aspiration device. Embolised 
debris includes necrotic atheromatous core, lipid-rich foam 
cells, cholesterol clefts, and fibrin, and most (80%) of them 
are < 100 μm in diameter. Larger particulate debris causes 
more plugging and compromise to myocardial perfusion 
than do smaller particles. These devices have pore sizes of 
between 100 and 110 μm and therefore capture particles 
> 110 μm and thereby protect against macroembolisation. 
However, their efficacy is not uniform because of the large 
crossing profile which further disrupts plaque and device-
-related trauma. Incomplete conduit occlusion or filter 
apposition, filter movement, incomplete aspiration, filter 
embolic overload, and side branch backwash are a few of 
the causes of incomplete embolic protection, even when 
used correctly.
The coronary bed, being an intermediately-sensitive 
vascular bed, can withstand ischaemia from distal em-
bolisation unless it is very intense in proportion, affects 
an extensive segment of the viable myocardium, or it is 
Figure 2. Saphenous vein graft was cannulated using 6 F Judkins 
right guiding catheter in straight lateral view
Figure 3A, B. Residual lesion despite repeated pre-dilatation with different balloons (A — straight lateral view; B — antero-posterior projection)
A B
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already a jeopardised myocardium with left ventricular 
dysfunction. Therefore, a normally functioning left ven-
tricular myocardium can withstand small-to-moderate 
intensity transient ischaemic insult without any con-
sequences, whereas even smaller territory transient 
ischaemia may be clinically significant in the setting of 
left ventricular dysfunction. Focal fibrotic lesions, aorto-
-ostial lesions, distal anastomotic lesions, and in-stent 
restenosis lesions have a low embolisation risk and can 
be treated without EPD.
A sole surviving graft, large area of viable myocardium 
supplied by the SVG, left ventricular dysfunction, or atrio-
ventricular nodal artery supply through the SVG in the 
absence of an artificial pacemaker all increase the clinical 
risk after an episode of slow flow. They should therefore be 
treated with EPD if feasible. This includes direct stenting, 
stent undersizing, the use of covered stent grafts, aspira-
tion thrombectomy, adjunctive administration of intragraft 
anti-thrombotic agents (abciximab and thrombolytics in 
setting of thrombus), and prophylactic use of vasodilators 
(verapamil, nicardipine, adenosine, and nitroprusside). 
These have yielded positive outcomes in anecdotal reports 
and small studies but their efficacy has not been confirmed 
in large randomised trials.
Figure 5. Saphenous vein graft to obtuse marginal showing 
TIMI III flow after successful stenting
Figure 4. Lesion was stented by deploying 3.5 × 23 mm Xience 
Prime everolimus-eluting stent at 13 atm pressure
Intragraft administration of vasodilators targets mic-
rovasculature to combat slow and no-reflow phenomena. 
Pre-treatment with intracoronary adenosine, a potent 
dilator of arteries and arterioles, decreases peri-procedural 
myocardial infarction after elective PCI because it improves 
myocardial flow and lowers the incidence of no-reflow in the 
setting of acute MI [5–8]. High doses of intragraft adenosine 
(at least five boluses of 24 μg each) may help to reverse 
slow and no-reflow phenomena in patients undergoing SVG 
intervention [9, 10]. Similar results have been observed with 
prophylactic administration of intragraft verapamil [11–14], 
and nicardipine [15] in reducing no-reflow in SVG PCI.
Based on these findings, we decided to try intragraft 
diltiazem to reduce slow flow in SVG PCI. This is also another 
calcium channel blocker like verapamil and nicardipine. 
The reason for success in our case was that the lesion was 
discrete, aorto-ostial, and fibrotic, as a cutting balloon was 
used to open up the lesion.
Therefore, if the morpho-anatomy is carefully assessed 
before attempting an SVG, one can achieve success without 
using an EPD.
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Streszczenie
Przezskórna interwencja wieńcowa (PCI) w obrębie wszczepionego pomostu żylnego wiąże się z wysokim ryzykiem oko-
łozabiegowego zawału serca i większą śmiertelnością niż rutynowe zabiegi tego typu w naczyniach natywnych. Zaleca 
się stosowanie urządzeń zabezpieczających przed zatorami w celu obniżenia ryzyka odległych zatorów w trakcie PCI 
w pomoście żylnym.
Autorzy przedstawili przypadek 72-letniego pacjenta, aktywnego palacza, z ostrym zespołem wieńcowym, u którego 3 
lata wcześniej wykonano chirurgiczne pomostowanie aortalno-wieńcowe. Powtórna koronarografia wykazała drożność 
stentu poza nieciągłą ekscentryczną krytyczną zmianą w miejscu połączenia pomostu z żyły odpiszczelowej z gałęzią 
brzeżną. Przez zwężenie przeprowadzono prowadnik angioplastyczny 0,014” typu runthrough (Terumo, Japonia). Przed 
każdą predylacją balonową i implantacją stentu do pomostu podawano diltiazem (5 mg) przez cewnik prowadzący (łącz-
na dawka = 30 mg). Ostatecznie w miejscu zwężenia umieszczono i rozprężono stent uwalniający ewerolimus Xience 
Prime 3,5 × 23 mm (Abbott, USA), stosując ciśnienie 13 atm. Uzyskano przepływ TIMI III. Pacjenta wypisano następnego 
dnia z zaleceniem przyjmowania następujących leków: kwasu acetylosalicylowego — 75 mg/dobę, tikagreloru — 90 mg 
2 razy/dobę, atorwastatyny — 40 mg/dobę, metoprololu — 100 mg/dobę i ramiprilu — 5 mg/dobę. Od czasu zabiegu 
chory czuł się bardzo dobrze i regularnie zgłaszał się na wizyty kontrolne do placówki autorów.
Słowa kluczowe: urządzenia do ochrony przeciwzakrzepowej, podanie diltiazemu do pomostu naczyniowego,  
przezskórna interwencja wieńcowa, pomostowanie aortalno-wieńcowe
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